CHF147.70
0.94% yesterday
SIX Swiss Exchange, Nov 21, 05:30 pm CET
ISIN
CH1335392721
Symbol
GALD
Index

Galderma Target price 2025 - Analyst rating & recommendation

Galderma Classifications & Recommendation:

Buy
79%
Hold
21%

Galderma Price Target

Target Price CHF163.20
Price CHF147.70
Potential
Number of Estimates 15
15 Analysts have issued a price target Galderma 2026 . The average Galderma target price is CHF163.20. This is higher than the current stock price. The highest price target is
CHF191.10 29.38%
register free of charge
, the lowest is
CHF129.28 12.47%
register free of charge
.
A rating was issued by 19 analysts: 15 Analysts recommend Galderma to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2026 of . Most analysts recommend the Galderma stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion CHF 3.59 4.26
7.86% 19.12%
EBITDA Margin 21.80% 22.37%
1.50% 2.61%

18 Analysts have issued a sales forecast Galderma 2025 . The average Galderma sales estimate is

CHF4.3b
Unlock
. This is
12.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF4.5b 18.45%
Unlock
, the lowest is
CHF4.0b 5.19%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF3.6b 7.86%
2025
CHF4.3b 19.12%
Unlock
2026
CHF5.0b 16.92%
Unlock
2027
CHF5.8b 16.06%
Unlock
2028
CHF6.5b 12.37%
Unlock
2029
CHF7.2b 10.90%
Unlock
2030
CHF7.8b 8.43%
Unlock
2031
CHF8.3b 6.68%
Unlock
2032
CHF8.9b 7.34%
Unlock

15 Analysts have issued an Galderma EBITDA forecast 2025. The average Galderma EBITDA estimate is

CHF953m
Unlock
. This is
11.18% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF1.0b 19.45%
Unlock
, the lowest is
CHF874m 1.56%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF783m 9.48%
2025
CHF953m 22.21%
Unlock
2026
CHF1.2b 29.67%
Unlock
2027
CHF1.6b 27.31%
Unlock
2028
CHF1.9b 21.51%
Unlock
2029
CHF2.2b 15.89%
Unlock
2030
CHF2.2b 1.05%
Unlock
2031
CHF2.4b 7.05%
Unlock
2032
CHF2.6b 9.38%
Unlock

EBITDA Margin

2024 21.80% 1.50%
2025
22.37% 2.61%
Unlock
2026
24.81% 10.91%
Unlock
2027
27.21% 9.67%
Unlock
2028
29.42% 8.12%
Unlock
2029
30.75% 4.52%
Unlock
2030
28.66% 6.80%
Unlock
2031
28.76% 0.35%
Unlock
2032
29.30% 1.88%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 0.79 2.49
515.79% 219.23%
P/E 59.77

16 Analysts have issued a Galderma forecast for earnings per share. The average Galderma EPS is

CHF2.49
Unlock
. This is
94.53% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF2.69 110.16%
Unlock
, the lowest is
CHF2.13 66.41%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF0.79 515.79%
2025
CHF2.49 219.23%
Unlock
2026
CHF3.61 44.98%
Unlock
2027
CHF4.86 34.63%
Unlock
2028
CHF6.16 26.75%
Unlock
2029
CHF7.31 18.67%
Unlock
2030
CHF6.71 8.21%
Unlock
2031
CHF7.19 7.15%
Unlock
2032
CHF7.90 9.87%
Unlock

P/E ratio

Current 115.39 107.04%
2025
59.77 48.69%
Unlock
2026
41.33 30.85%
Unlock
2027
30.67 25.79%
Unlock
2028
24.21 21.06%
Unlock
2029
20.39 15.78%
Unlock
2030
22.23 9.02%
Unlock
2031
20.73 6.75%
Unlock
2032
18.88 8.92%
Unlock

Current Galderma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
Locked
Locked Sep 04 2025
BERENBERG
Locked
Locked
Locked Jul 31 2025
JEFFERIES
Locked
Locked
Locked Jul 18 2025
JEFFERIES
Locked
Locked
Locked Jul 17 2025
BERENBERG
Locked
Locked
Locked Jul 02 2025
BERENBERG
Locked
Locked
Locked Jul 01 2025
BERENBERG
Locked
Locked
Locked Apr 01 2025
Analyst Rating Date
Locked
JEFFERIES:
Locked
Locked
Sep 04 2025
Locked
BERENBERG:
Locked
Locked
Jul 31 2025
Locked
JEFFERIES:
Locked
Locked
Jul 18 2025
Locked
JEFFERIES:
Locked
Locked
Jul 17 2025
Locked
BERENBERG:
Locked
Locked
Jul 02 2025
Locked
BERENBERG:
Locked
Locked
Jul 01 2025
Locked
BERENBERG:
Locked
Locked
Apr 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today